Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8647181 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL8647178 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL19477874 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL5148124 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL2338780 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL20643514 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL10036857 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL19477779 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL22537923 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL21762059 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20220175934-A1 | MULTIVALENT LIGAND CLUSTERS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | MITOTHERAPEUTIX LLC | 2022-06-09 | — | — | US | disclosed |
| WO-2015006740-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| US-8658211-B2 | Polyconjugates for in vivo delivery of polynucleotides | Arrowhead Madison Inc. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8541548-B2 | Delivering nucleic acids to cells; complexing nucleic acid with polyampholte; contacting cell; biocompatible in vivo delivery; gene therapy | Arrowhead Madison Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120230938-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | Arrowhead Madison Inc. (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012089602-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
| EP-2061443-A2 | POLYCONJUGATES FOR IN VIVO DELIVERY OF POLYNUCLEOTIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-05-27 | — | — | EP | disclosed |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080281041-A1 | Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080269450-A1 | Endosomolytic Poly-Beta-Aminoester Polymers | ROCHE MADISON INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2008022309-A2 | POLYCONJUGATES FOR IN VIVO DELIVERY OF POLYNUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175934-A1 | MULTIVALENT LIGAND CLUSTERS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | ATIC, PCNA, FOLR1 | LMNA 3132/4885KMT2A 3119/4885POLB 1009/4885 |
| US-20120230938-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | PHAX, NCL, PCBP1 | LMNA 281/4885KMT2A 4050/4885POLB 346/4885 |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | HDAC6, CD47, AADAC | LMNA 2711/4885KMT2A 2994/4885POLB 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.